FOLLISTIM AQ Rx
Generic Name and Formulations:
Follitropin beta (recombinant follicle-stimulating hormone) 75 IU, 150 IU; per vial; soln for SC or IM inj.
Merck & Co., Inc.
Indications for FOLLISTIM AQ:
Stimulation of multiple follicles in ovulatory patients undergoing Assisted Reproductive Technologies (ART). Induction of ovulation in patients with functional anovulatory infertility that is not due to ovarian failure.
Individualize. ART: initially 150–225 IU daily in the early follicular phase (at least first 4 days), then adjust based on response; max 600 IU. Ovulation induction: initially 75 IU daily for up to 14 days; then adjust weekly by 37.5 IU based on response; max 300 IU. Both: induce final maturation of follicles or ovulation with 5000–10000 IU of hCG (see Precautions).
Ovarian failure. Uncontrolled thyroid or adrenal disease. Undiagnosed abnormal vaginal bleeding. Ovarian cysts or enlargement. Tumor of pituitary, breast, ovary, or uterus. Streptomycin or neomycin allergy. Pregnancy (Cat.X).
Do complete gynecological and endocrinological exam first. Thromboembolic disorders. Do not give hCG if high estrogen levels or excessive numbers of ovarian follicles by ultrasound indicate a high risk of ovarian hyperstimulation syndrome (OHSS). Nursing mothers: not recommended.
OHSS with pulmonary and vascular complications, ovarian enlargement or cysts, abdominal pain (discontinue if occurs), local reactions, risk of high order multiple births.
Vials (0.5mL)—1; Cartridge (w. needles)—1; Follistim Pen (w. needles)—1
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|